Clinical trials: Choroidal Diseases
Choroidal Neovascularization, Age-related Macular Degeneration
An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO
This was an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported here) enrolled patients with primary or recurrent Choroidal Neovascularization (CNV)…
- Trial name
- NCT00379795
- Testing
- Ranibizumab 0.5 mg
- Volunteers
- 853 people
- Sponsor
- Genentech, Inc.
Healthy
Chronic Cardiovascular and Gut-bacteria Effects of Phenolic Rich Oats in Adults With Above Average Blood Pressure
In this proposed human trial, the investigators aim to establish whether 4 weeks of daily consumption of beta-glucan matched meals providing either a high dose or a moderate dose of oat avenanthramides and phenolic acids leads to…
- Trial name
- NCT02847312
- Testing
- High avenanthramide, phenolic acid, Low avenanthramide, medium phenolic acid, Control
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Reading
Pseudoxanthoma Elasticum
Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
This study aims to systematically assess the retest reliability and ability to detect a change of new visual function tests and ophthalmological imaging methods for observing the natural course of pseudoxanthoma elasticum (PXE).
- Trial name
- PROPXE (NCT05662085)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- University Hospital, Basel, Switzerland
Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD)
A Study Of Early Markers Of Choroidal Neovascularization
Identify early markers of choroidal neovascularization (CNV) in the fellow eye of a patient with CNV in the other eye due to age-related macular degeneration with the expectation of being able to identify patients in need of…
- Conditions
- Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD), Early Markers
- Trial name
- NCT00902785
- Testing
- no drug
- Where
- 3 sites in Italy, Portugal and 1 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Polypoidal Choroidal Vasculopathy
Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
To determine long-term outcomes, recurrence rates, and treatment needs in Polypoidal Choroidal Vasculopathy (PCV). Specifically, to describe the long-term outcomes, recurrence rates and treatment patterns PCV patients 5 years…
- Trial name
- NCT03929731
- Testing
- Indocyanine Green Angiography
- Where
- 3 sites in Singapore
- Volunteers
- 72 people
- Sponsor
- Singapore National Eye Centre
Myopia
Choroidal Response to the Modified Defocus Incorporated Multiple Segments Spectacle Lenses
The goal of this study is to investigate the short-term changes in choroidal thickness and efficacy of the study spectacle lenses in children.
- Trial name
- NCT07547072
- Testing
- Modified Defocus Incorporated Multiple Segments lens (D1), Modified Defocus Incorporated Multiple Segments lens (D2)
- Where
- Hong Kong
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Ocular Melanoma, Choroidal Melanoma
Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone
Patients diagnosed with ocular melanoma consent to participate in the study. Combined PET/CT scans of the whole body are performed at baseline, three months later, and six months after that for a total of three combined scans in…
- Conditions
- Ocular Melanoma, Choroidal Melanoma, Uveal Melanoma
- Trial name
- NCT00351728
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Age-related Macular Degeneration
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
The purpose of this study was to evaluate the efficacy and safety of two different brolucizumab 6 mg dosing regimens in patients with visual impairment due to age-related macular degeneration (AMD) who have previously received…
- Trial name
- FALCON (NCT04679935)
- Testing
- Brolucizumab
- Where
- 19 sites in Germany, Switzerland
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Wet Age-related Macular Degeneration, Age-related Macular Degeneration
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
The objective of this study is to confirm the safety and to establish the effectiveness of low voltage external beam radiosurgery using the IRay System for the treatment of subjects with recurrent leakage secondary to neovascular…
- Conditions
- Wet Age-related Macular Degeneration, Age-related Macular Degeneration, AMD, Wet AMD
- Trial name
- NCT01339949
- Testing
- IRay
- Where
- 3 sites in Italy, United Kingdom
- Sponsor
- Oraya Therapeutics, Inc.
Choroidal Neovascularization
Bevacizumab Effect on Blood Velocity
Retinal blood flow velocity is affected by Bevacizump intravitreal injection. This effect is correlated to treatment success.
- Trial name
- NCT01298440
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Optical Imaging, Ltd.
Diabetic Retinopathy, Glaucoma
AI for the Detection of Retinal Disease and Glaucoma in Patients With Diabetes Mellitus in Primary Care
Background: Diabetic retinopathy (DR) is one of the most important causes of blindness worldwide, especially in developed countries.
- Conditions
- Diabetic Retinopathy, Glaucoma, Age-Related Macular Degeneration, Choroidal Nevus
- Trial name
- NCT04132401
- Testing
- algorithm
- Where
- Spain
- Volunteers
- 902 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Age-Related Macular Degeneration
A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
AG-013,958 is being studied to treat patients with Age-Related Macular Degeneration. A total of 144 subjects may be enrolled in the trial.
- Trial name
- NCT00090532
- Testing
- AG-013,958
- Where
- 39 sites in United States, Australia and 2 more
- Volunteers
- 155 people
- Sponsor
- Pfizer
Choroidal Nevi, Uveal Melanoma
BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma
The BAP1 trial will examine the blood of patients diagnosed with choroidal nevi or uveal melanoma for a germline BAP1 mutation and other genetic markers associated with developing malignancy as well as additional sequencing of…
- Trial name
- NCT01925599
- Where
- 3 sites in United States
- Volunteers
- 133 people
- Sponsor
- Amy C Schefler, MD
Choroidal Neovascularization, Uveitis
Conbercept in Choroidal Neovascularization Secondary to Uveitis
The investigators hypothesize that it is safe and effective to treat patients with choroidal neovascularisation (abnormal blood vessels growing under the retina) secondary to uveitis with Conbercept.
- Trial name
- NCT02934841
- Testing
- Conbercept
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Chongqing Medical University
Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
This study compared the effect of ranibizumab administered as monotherapy versus ranibizumab administered in combination with verteporfin photodynamic therapy (PDT) on visual acuity in patients with symptomatic macular polypoidal…
- Trial name
- EVEREST II (NCT01846273)
- Testing
- Ranibizumab, Verteporfin PDT
- Where
- 41 sites in Hong Kong, Japan and 5 more
- Volunteers
- 321 people
- Sponsor
- Novartis Pharmaceuticals
Choroid Neovascularization, Age-Related Macular Degeneration
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
- Trial name
- NCT00395057
- Testing
- AGN 211745, Ranibizumab 500µg
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 138 people
- Sponsor
- Allergan
Macular Degeneration, Choroidal Neovascularization
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in…
- Trial name
- NCT00436553
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 43 sites in United States, Canada
- Volunteers
- 321 people
- Sponsor
- Novartis
Age-Related Macular Degeneration
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.
- Trial name
- NCT02387957
- Testing
- Fovista®, bevacizumab, ranibizumab
- Where
- 24 sites in United States
- Volunteers
- 63 people
- Sponsor
- Ophthotech Corporation
Age Related Macular Degeneration
A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy
The objective of the MERITAGE Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration…
- Trial name
- MERITAGE (NCT00809419)
- Testing
- NeoVista Ophthalmic System
- Where
- 5 sites in United States, Israel and 1 more
- Volunteers
- 32 people
- Sponsor
- NeoVista
Macular Degeneration
Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Prospective, multi-center 2-stage study. Stage 1 (Phase I) is open-label with all patients treated with the NT-503-3 ECT implant. Stage 1 (Phase I) patients will undergo explantation at year 2.
- Trial name
- NCT02228304
- Testing
- NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
- Where
- 38 sites in United States, Israel
- Volunteers
- 42 people
- Sponsor
- Neurotech Pharmaceuticals